Immunogenicity of the pentavalent rotavirus vaccine among infants in two developing countries in Asia, Bangladesh and Vietnam
ABSTRACT Background: We evaluated the immunogenicity of the pentavalent rotavirus vaccine (PRV) in two GAVIeligible
Asian countries, Bangladesh and Vietnam, nested in a larger randomized, double-blind, placebocontrolled
efficacy trial conducted over a two-year period from 2007 through 2009.
Methods: 2036 infants were randomly assigned, in a 1:1 ratio, to receive three oral doses of PRV or
placebo approximately at 6, 10, and 14 weeks of age. Concomitant use of EPI vaccines, including oral
poliovirus vaccine (OPV) and diphtheria-tetanus-whole cell pertussis (DTwP) vaccine, was encouraged
in accordance to the local EPI schedule. A total of 303 infants were evaluated for immunogenicity and
blood samples were collected before the first dose (pD1) and approximately 14 days following the third
dose (PD3). The seroresponse rates (≥3-fold rise from pD1 to PD3) and geometric mean titers (GMTs)
were measured for anti-rotavirus immunoglobulin A (IgA) and serum neutralizing antibody (SNA) to
human rotavirus serotypes G1, G2, G3, G4, and P1A, respectively.
Results: Nearly 88% of the subjects showed a
≥3-fold increase in serum anti-rotavirus IgA response in
the analysis of the two countries combined. When analyzed separately, the IgA response was lower in
Bangladeshi children (78.1% [95% CI: 66.0, 87.5]) than in Vietnamese children (97.0% [95% CI: 89.6, 99.6]),
with a PD3 GMT of 29.1 (units/mL) and 158.5 (units/mL), respectively. In the combined population, the
SNA responses to the individual serotypes tested ranged from 10 (G3) to 50 (G1) percentage points lower
than the responses shown in the developed countries. However, the SNA response to G3 in Vietnamese
subjects was 37.3% (95% CI: 25.8, 50.0), which was similar to the G3 response rate in developed countries.
Conclusions: Three oral doses of PRV were immunogenic in two GAVI-eligible Asian countries: Bangladesh
and Vietnam. The GMTs of both the serum anti-rotavirus IgA and SNA responses were generally higher
in Vietnamese than in Bangladeshi children. The SNA responses varied by individual serotypes and were
lower than the results from developed countries. The clinical significance of these observations is not
understood because an immune correlate of protection has not been established.
[Show abstract] [Hide abstract]
ABSTRACT: OBJECTIVES: Rotavirus is the most important etiology of severe diarrhea in Bolivia. The monovalent attenuated human oral rotavirus vaccine Rotarix(®) was introduced in Bolivia in 2008. We describe the molecular epidemiology of circulating rotavirus strains before vaccine introduction. METHODS: Two thousand one hundred thirty-five diarrheal samples were collected from hospitals in four Bolivian cities during 2007-2008. Forty-three percent (445 of 1030 rotavirus-positive samples) were analyzed for G and P genotypes. Among those, 331 were electropherotyped by polyacrylamide gel electrophoresis. Disease severity was quantified using a modified Vesikari scale. RESULTS: Among the 445 samples, five genotypes were found to be prevalent: G9P (33%), G1P (17%), G2P (13%), G9P (12%), and G1P (4%). Co-infections with two or more strains accounted for 14% of samples. The most prevalent strain, G9, showed greater electropherotype diversity compared to other serogroups. Strain G1P generally infected younger children and peaked later in the year than other strains. No particular genotype was associated with a higher severity score, though there was a significant difference in the duration of diarrhea between genotypes. CONCLUSIONS: During the 2-year pre-vaccine period, substantial diversity of rotavirus co-circulating strains was observed. These data constitute a baseline against which changes in circulating strains post-vaccine introduction can be monitored.International journal of infectious diseases: IJID: official publication of the International Society for Infectious Diseases 05/2013; 17(9). DOI:10.1016/j.ijid.2013.03.016 · 2.33 Impact Factor
Vaccine 04/2012; 30 Suppl 1:A1-2. DOI:10.1016/j.vaccine.2011.10.108 · 3.49 Impact Factor
[Show abstract] [Hide abstract]
ABSTRACT: Rotavirus infections, prevalent in human populations worldwide are mostly caused by Group A viruses. Live attenuated rotavirus vaccines are highly effective in preventing severe rotavirus gastroenteritis. However, the cost of these vaccines and local availability can be a barrier for widespread adoption in public health programs in developing countries where infants suffer a heavy burden of rotavirus related morbidity and mortality. A phase I/II study was carried out with the long term aim to produce a locally licensed vaccine which is equally safe and immunogenic as compared to available licensed vaccines.Vaccine 08/2014; 32:A117–A123. DOI:10.1016/j.vaccine.2014.03.069 · 3.49 Impact Factor